Veru Inc. VERU · NASDAQ
$2.13 -2.74% (-$0.06)
Summary
44 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $23.9M against $2.68M.
- The share price is below the Bulios Fair Price.
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Is it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $13.6M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $4 is 88% above today's price. 86% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Global public health sector 86%
- U.S. prescription channel 14%
By region
- UNITED STATES 32%
- Other Geographical Areas 28%
- BRAZIL 16%
- MOZAMBIQUE 13%
- SOUTH AFRICA 11%
Global public health sector brings in 86% of revenue.
Segments in detail